Bangkok--18 Sep--image impact
Queen Saovabha Memorial Institute, BioNet-Asia and Liaoning Cheng Da Biotechnology jointly announce a collaboration to manufacture the next generation Rabies vaccine in Thailand.
The rabies vaccine manufacturing collaboration was signed today between Queen Saovabha Memorial Institute (QSMI) of the Thai Red Cross Society, BioNet-Asia (BioNet) and Liaoning Cheng Da Biotechnology (CDBIO). This tripartite partnership marks a new milestone in technological collaboration between Thailand and China in the field of vaccine development and manufacturing.
Rabies remains a major public health concern in Thailand, calling for the need of locally manufactured highly purified cell-culture rabies vaccine. After a few years of joint development, this rabies project is finally moving forward to the ultimate phase of manufacturing in QSMI facilities.
Prof. Dr. Visith Sitprija, Director of QSMI, said: “We are delighted to cooperate with BioNet and CDBIO on this project which will benefit the people of Thailand. Through this partnership, QSMI will be able to manufacture rabies vaccine in its production plant and supply it along with the currently produced rabies immunoglobulin.”
Mr. Li Ning, Director of CDBIO, added: “We are proud that QSMI and BioNet selected our company and technology for this Rabies Manufacturing Project in Thailand. Our vaccines against Rabies and Japanese Encephalitis, using chromatographically purified cell-culture technology, have been widely used in Asia. We are confident that this strategic manufacturing partnership will pave the way to building bridges between our two countries and to support the vaccine industry in Thailand.”
Mr. Vitoon Vonghangool, Managing Director of BioNet, concluded: “BioNet, has constantly been an advocate for vaccine manufacturing partnerships in Asia and therefore we are honoured to collaborate with QSMI and CDBIO, two institutions both internationally recognized in the field of rabies and cell-culture technology. The clinical results of CDBIO highly purified Rabies vaccine have led to this joint initiative of locally developing and manufacturing this new Rabies vaccine using the same innovative technology.”
For further information, please contact:
BioNet-Asia Co., Ltd.
Tel: +66 2361 8110
E-mail: info@bionet-asia.com
www.bionet-asia.com
Liaoning Cheng Da Biotechnology Co., Ltd.
Tel: 0086-24-83787033
E-mail: cdbio@cdbio.cn
www.cdbio.cn
Queen Saovabha Memorial Institute
Tel: +66 2252-0161
E-mail: info@saovabha.com
www.saovabha.com